Strong order book, soft execution—capacity ramp-up is the make-or-break
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Prior 35-40% FY27 growth target reduced to 25%; Q1 YoY revenue only 8.1%, well below reset guidance trajectory
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong order book (₹6,630 Cr, +26% YoY) and healthy inquiries (₹23,000 Cr) underpin medium-term growth, but Q1 execution (10% YoY revenue, 4.7% PAT decline) and capacity utilization gap (Moraiya 57%, Changodar 27% vs ₹6,600 Cr execution need) raise near-term concerns. FY27 guidance downgrade from 35-40% to 25% signals reset expectations. Backward integration (200-300 bps margin uplift from FY28) is credible but delays near-term accretion.
₹572.3 Cr
Revenue · +8.1% YoY₹64.3 Cr
Reported PAT · −4.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
10% YoY revenue growth delivers on order execution
OVERSTATED10% YoY is far below prior 35-40% FY27 guidance; QoQ fell 26.9%
16% EBITDA margin consistency shows pricing discipline
PartialQ1 standalone 15.6%, consolidated 19.2% (subsidiary boost); guidance 16% is flat vs prior 15-17% range
Changodar capacity constraints are purely temporary, Q3 onwards growth accelerates
PartialChangodar at 27% utilization Q1, expected 60-65% rest of year; unproven ramp timeline
₹6,630 Cr order book with 26% YoY growth shows demand strength
METOrder book figure confirmed; 26% growth supports medium-term visibility
PAT margin of 8.9% standalone reflects operational leverage
MISSPAT down 4.7% YoY despite revenue +8.1% shows margin compression, not leverage
Earnings quality
What changed since the last call
FY27 revenue growth guidance downgraded
DowngradePrior call: 35-40% growth, ₹3,250 Cr target. New: 25% growth. Q1 delivered 8.1% YoY. Implies ~₹3,125 Cr FY27, well below prior aspiration.
Backward integration margin benefit timing pushed
NeutralTargetted 200-300 bps uplift now starts FY28 (from Q1 FY28 commissioning), not in FY27. Q1 standalone EBITDA 15.6% reflects absence of benefit.
$1B revenue target now ₹8,000 Cr equiv.
NeutralOriginally $1B; management cites rupee depreciation since prior call. Now targets ₹8,000 Cr by FY29 (vs ₹9,600 Cr at original $1B). Pathway clearer but target lower in rupees.
EBITDA margin guidance flat vs prior range
DowngradePrior: 15-17% stable with 150-300 bps expansion medium-term. New FY27: 16% standalone. No near-term accretion from backward integration.
The Q&A
Analysts pressed hard on capacity utilization gap (why Moraiya only 57% despite big order book), quarterly revenue miss vs guidance, and PAT decline despite revenue growth. Management deflected with 'geopolitical issues' and 'temporary Changodar headwinds' but offered no hard justification for Moraiya underperformance. CFO specific on numbers; MD broader. Call felt defensive rather than confident.
Revenue miss, capacity — Abhijeet Singh, Systematix
PartialMainly Changodar expansion; new facilities start August '26. Raw materials sourced through December via bulk procurement. Geopolitical not a major headwind.
Inventory and working capital — Abhijeet Singh, Systematix
AnsweredTemporary to protect against geopolitical risk until backward integration is live. Will reduce from Q4 FY28.
FY27 guidance — Subhadip Mitra, Nuvama
AnsweredConfirmed 25% revenue, 16% EBITDA, 10% PAT margin. FY29: $1B (₹8,000 Cr). FY28 guidance in Q4 call.
PGCIL mega-order — Jainam Vora, Saltoro Investment Advisors
PartialWon via L1 bidding. ₹23,000 Cr inquiries under negotiation, 10-15% win ratio. Expect more such orders.
Employee cost variance — Shivam Singh, Capital Arc
AnsweredQ4 had ESOP and MD commission provisions. Q1 already accrued. No structural change.
High-margin order selectivity — Shivam Singh, Capital Arc
Partial16% EBITDA is consistent with FY26 full-year and Q4 FY27. This will continue.
Revenue by rating class — Prathamesh, Motilal Oswal
AnsweredOrder book fairly spread 66-765 kV. This quarter heavier on 220/400/765 kV due to Changodar constraints. Will normalize post-Aug.
Backward integration ROI — Darshil Jhaveri, Crown Capital
AnsweredYes, 200-300 bps from FY28 onwards. Facilities come up Q1-Q4 FY28. Depreciation will hit FY28.
Order execution timeline — Balasubramanian, Arihant Capital
AnsweredMost orders still 18-24 months. PGCIL order exceptional, not trend. Win ratio 10-15% on ₹23,000 Cr pipeline.
Raw material protection — Gaurav Khemka, Mars Ventures
AnsweredInventory temporary for geopolitical protection through December. Backward integration will reduce it from Q4 FY28.
EBITDA margin clarity — Vaibhav Mishra, Finvestors
Answered16% includes other income, standalone transformer business. Consolidated may be 20-21% due to subsidiary.
Order margin protection — Vaibhav Mishra, Finvestors
AnsweredPrice variation clause protects. Also stocked inventory through December for large orders.
Debt and working capital capacity — Yash Gupta, Asit Koticha Family Office
PartialFinance lease ₹500 Cr of ₹1,000 Cr capex. Internal accruals + squeeze working capital cycle. Debt will not increase materially.
HVDC ramp timeline — Avikshit Vijay, Global Consilient Research
Answered15-16 months to full manufacturing. 9 months to complete repair work. Then PGCIL trial order. Revenue 2027-28 onwards.
$1B reconciliation — Avikshit Vijay, Global Consilient Research
PartialFY29 is earliest; path is ₹6,000 Cr transformer + ₹1,000 Cr backward integration = ₹8,000 Cr (≈$1B at current rupee). Rupee was different when prior target set.
Capacity utilization gap — Shrinarayan Mishra, Baroda BNP Paribas AMC
DodgedNo major reason. Will improve to 80-85% going forward. We are in line with market growth.
Mix-driven margin risk — Shrinarayan Mishra, Baroda BNP Paribas AMC
PartialNo possibility of margin decline. We are protected by ₹6,630 Cr order book.
CRGO anti-dumping — Pratham Modi, HPMG Shares and Securities
DodgedInvestigation ongoing, won't comment now. Protected our inventory until December. Things will get sorted by then.
Changodar capacity reality — Rahulkumar Mishra, Antique Stock Broking
AnsweredFY27: 60-65%. FY28: 80-85% as backward integration comes online.
USA market strategy — Bhavya Dedhia, KRIIS PMS
AnsweredMajor supplier 765 kV, 20+ years track record. Compete on quality, production capability, price. Will maintain 10-15% export mix.
Working capital days outlook — Rahul Chandak, Alpha Plus Capital
AnsweredReceivables reduced in April. Targeting 120-130 days working capital days going forward.
$1B vs INR guidance — Basant Bansal, NBG Investment
PartialWhen $1B target set, rupee was low. Now targeting ₹8,000 Cr (≈$1B). From ₹5-6,000 Cr capacity + ₹800-1,000 Cr backward integration.
Consolidated margin guidance — Viren Sameer Deshpande, Alphapeak Investment
Answered16% is standalone only. Subsidiary contributes ~100 bps uplift. Consolidated should be higher than FY26's 17.3%.
Moraiya utilization mystery — Arun, ABDS Capital
PartialGeopolitical issues in past quarter; constrained at 57%. Now protected through December. Expect material improvement Q2 onwards.
Guidance
FY27: 25% growth (₹~3,125 Cr implied from ₹2,500 Cr FY26 base)
MediumDowngraded from prior 35-40% target (₹3,250 Cr). Contingent on Changodar ramp from 27% to 60-65% utilization by year-end and Moraiya reaching 80-85% FY28.
FY29: ₹8,000 Cr (approx $1 billion at current rupee rates)
MediumPath: ₹5-6,000 Cr from transformer expansion + ₹800-1,000 Cr from backward integration third-party sales. Rupee depreciation since prior $1B target set now makes target ₹8,000 Cr vs ₹9,600 Cr.
FY27 EBITDA: 16% standalone, 20-21% consolidated
MediumFlat vs prior 15-17% range. Q1 delivered 15.6% standalone (19.2% consolidated). No margin accretion until backward integration facilities live in FY28.
PAT margin FY27: 9-10%
MediumQ1 delivered 8.9% standalone. Guidance implies modest accretion from operational leverage and order mix, assuming Changodar ramp.
FY28 backward integration margin uplift: 200-300 bps
MediumStarts Q1 FY28 as facilities come online. Gradual accretion as utilization scales. Depreciation impact will offset some benefit in FY28.
Changodar expansion: ₹150 Cr, completion Aug 2026
MediumDelays already occurred (monsoon, labor, engineering enhancements). Now on 'revised execution schedule' per management.
Backward integration: ₹900-1,000 Cr total, phased through FY28
MediumFinance lease: ₹500 Cr. QIP proceeds: ₹145 Cr. Internal accruals + small debt if needed. To be funded mix of QIP, leasing, internal cash, minimal debt.
Risks the call surfaced
Execution risk—capacity ramp
HighChangodar at 27% utilization, targeted 60-65% rest of FY27. Delayed plant commissioning history (monsoon, labor, engineering mods). Failure to ramp means ₹6,630 Cr order book execution delays and missed revenue targets.
Revenue delivery risk
HighPrior FY27 guidance 35-40% revenue growth downgraded to 25%; Q1 YoY only 8.1%, QoQ -26.9%. Implies sequential miss of ₹500-600 Cr annual revenue vs prior guide. Risk: further downgrades if Changodar ramp fails.
Margin compression risk
MediumPAT -4.7% YoY despite revenue +8.1% signals margin squeeze. Q1 standalone EBITDA 15.6% below guidance 16%; PAT 8.9% vs FY27 target 9-10%. Risk: commodity inflation, unfavorable product mix (lower-rated units from Changodar when live), or pricing pressure.
Raw material and supply chain risk
MediumCRGO steel imports subject to DGTR anti-dumping investigation; outcome uncertain. Geopolitical disruptions cited as reason for high inventory (₹561 Cr FY26, elevated in Q1). Risk: tariff imposition could add 5-10% to raw material costs if import-dependent sourced materials get hit.
Backward integration execution risk
Medium₹900-1,000 Cr backward integration capex spanning CTC (Q2 FY27), Pressboard (Q3), Bushing (Q4), Fabrication (Q1 FY28). Prior history of delays at Changodar; margin benefit (200-300 bps) contingent on flawless ramp-up and market demand for 60-65% third-party sales.
Working capital deterioration
MediumWorking capital cycle at 170 days (inventory 85 days, receivables 130 days). Inventory deliberately elevated through December 2026 for geopolitical protection; receivables elevated due to milestone-based billing of large transformer contracts. Risk: liquidity strain if order execution delays or receivables collection deteriorates.
Management
Score 6/10. Transparent on order book and capex timelines; candid on Changodar delays (monsoon, labor, engineering mods). But vague on Moraiya utilization gap (said 'no major reason' when asked why only 57% despite big order book). Deflected on CRGO anti-dumping and HVDC specifics, saying 'won't comment now' and 'wait and see'. Appointed EY for IR support, signaling openness to governance. Track record mixed: prior 35-40% FY27 revenue guidance revised down to 25%; Q1 delivered only 8.1% YoY. Changodar expansion has slipped multiple times (now on 'revised schedule'). However, order book growth (26% YoY) and inflow (218% YoY) show strong sales execution. PAT down 4.7% YoY despite revenue growth indicates execution quality gap (margin/cost control weaker than revenue growth).
1 · Aug 2026
Changodar new facility commissioning; utilization ramp begins
2 · Q2 FY27
CTC facility (8,000 MTPA Phase I) commissioned; backward integration kickoff
3 · Q3 FY27
Management expects growth to pick up; Pressboard facility (5,000 MTPA) commissioned
Backward integration (200-300 bps margin uplift from FY28) is credible but delays near-term accretion.
Strong Orders, Weak Ramp—Capacity Execution Risk
TARIL's ₹6,630 Crore order book (+26% YoY) looks formidable, but Q1 revenue grew just 8.1%—half the pace needed to hit the revised 25% FY27 guidance. The gap between order visibility and plant utilization is the quarter, and management's explanation doesn't hold.
₹572.3 Cr
+8.1% YoY
Lagging
8.1% pace ≠ 25% required
₹6,630 Cr
+26% YoY
Critical
Moraiya 57%, Changodar 27%
TARIL's earnings print arrived with two faces. The order book (+26% YoY to ₹6,630 Cr) and Q1 inflow (₹2,114 Cr, anchored by a ₹1,000+ Crore PGCIL mega-order) told one story: robust demand and pricing power. But the revenue print (₹572.3 Cr, +8.1% YoY) and profitability (PAT ₹64.3 Cr, -4.7% YoY) told another. The gap between order visibility and execution is the quarter, and management's explanation—temporary Changodar capacity constraints—doesn't reconcile with Moraiya's persistent underutilization (57% in Q1, expected to stay 60–65% through FY27). When pressed why a plant with a ₹6,630 Crore order book runs at half of competitor capacity, the CFO said: 'no major reason.' That deflection cost the stock 11.93% by day 3.
Where the guidance miss came from
In Q4 FY26, management guided for 35–40% revenue growth in FY27, targeting ₹3,250 Crore. That was revised down to 25% growth (₹3,125 Cr implied) on this call. Q1 already shows the trajectory is adrift: at 8.1% YoY growth, the quarter would need to accelerate dramatically to hit the reset target. Management attributed the shortfall to Changodar plant expansion (27% utilization in Q1, ramp expected to 60–65% by year-end). Fair. But Moraiya, the larger and fully operational plant, is also at only 57% utilization. Management has a history of delays at Changodar (monsoon, labor, engineering mods), and the 'revised execution schedule' is now the third timeline shift. More troubling: the company has already downgraded guidance once; if Q2 revenue remains in the 8–12% YoY range, a second cut to 15–20% growth is probable, straining the ₹8,000 Crore FY29 target.
Profitability fell despite revenue growth
TARIL's PAT declined 4.7% YoY despite revenue growing 8.1%—a red flag for margin compression. Q1 consolidated EBITDA was ₹110 Cr (19.2% margin), but the subsidiary cushions the transformer business. Standalone transformer EBITDA was ₹87 Cr (15.6%)—below the 16% FY27 guidance. Management claims pricing discipline via price variation clauses, but the PnL contradicts this. PAT margin of 8.9% in Q1 is below the 9–10% FY27 guidance. The stated remedy: backward integration (CTC Q2, Pressboard Q3, Bushing Q4, Fabrication Q1 FY28) will unlock 200–300 basis points of margin uplift from FY28 onwards. None of that accretion is visible in Q1, and it's contingent on facility ramps that haven't yet happened. Worse, depreciation will offset some benefit in FY28, delaying the full 200–300 bps until FY29. Working capital is stretched to 170 days (inventory 85 days, receivables 130 days) due to deliberate raw material hoarding through December 2026 for geopolitical protection. This inflates short-term financing costs.
10% YoY revenue growth delivers on order execution
OverstatedQ1 at 8.1% YoY, well below 25% annualized guidance trajectory. QoQ -26.9%.
16% EBITDA margin shows pricing discipline
PartialQ1 standalone EBITDA 15.6%; flat vs prior 15–17% range. No accretion yet.
Changodar constraints are temporary; growth accelerates Q3+
PartialChangodar at 27%, targeted 60–65% by year-end. History of delays (monsoon, labor, engineering). Unproven ramp timeline.
₹6,630 Cr order book shows demand strength
SupportedOrder book confirmed; +26% YoY growth, ₹2.1 Cr Q1 inflow. ₹23,000 Cr pipeline under negotiation.
PAT margin of 8.9% reflects operational leverage
ContradictedPAT down 4.7% YoY despite revenue +8.1%. Margin compression, not leverage.
Price variation clauses protect order margins
PartialPAT decline and inventory hoarding through Dec 2026 suggest cost pressure unmitigated by pricing.
What changed on this call
Three substantive shifts from prior guidance:
FY27 revenue growth revised down: 35–40% → 25%. Absolute target ₹3,250 Cr → ~₹3,125 Cr. Q1 delivered 8.1% YoY; gap widens each quarter.
Backward integration margin benefit pushed to FY28: Originally targeted FY27; now deferred. Q1 EBITDA remains 15.6% standalone. Facilities come online Q2–Q4 FY27, but 200–300 bps benefit doesn't materialize until FY28 onwards.
$1B revenue target reframed as ₹8,000 Cr: Original $1B guidance implied ₹9,600 Cr. Management now cites rupee depreciation since prior call; ₹8,000 Cr is the FY29 aspiration (₹600 Cr lower in rupee terms).
Management frames these downgrades as 'being realistic' rather than a miss, but the pattern is clear: expectations have reset downward twice, execution lags guidance, and the turnaround levers (backward integration, capacity ramp) are yet to fire.
How the street reacted
The market rejected the print decisively. On day 1 after the announcement, the stock fell 5.16% from the pre-result close of ₹333.55. By day 3, the decline had widened to 11.93%, landing the stock at ₹295.7. This is not a snap-back sell-off—it's a repricing downward. The stock now trades 41% below its all-time high (₹501.25), well below its 20-day (₹332.57), 50-day (₹323.85), and 200-day (₹316.78) moving averages. RSI of 28.5 signals oversold conditions, but the market's message is unambiguous: the execution risk is real, and Q1 did not dispel it. FII ownership has declined from 11.33% (Q4 FY25) to 8.33% (Q4 FY26)—a 300 basis point trimming by foreign investors. Domestic institutional ownership has also waned (4.19% DII in Q3 FY26 → 1.77% in Q4 FY26). Even local money doubts the near-term story.
₹6,630 Crore order book (+26% YoY) provides 18–24 month execution visibility
Q1 inflow ₹2,114 Cr (+218% YoY) driven by PGCIL mega-order and export wins
USA export footprint (20+ year 765 kV track record) opens new revenue stream (10–15% target)
Backward integration roadmap concrete (CTC, Pressboard, Bushing, Fabrication phased commissioning)
FY27 guidance downgraded 35–40% → 25%; Q1 delivered 8.1%, widening gap
PAT fell 4.7% YoY despite revenue +8.1%; margin compression, not operating leverage
Capacity utilization unexplained (Moraiya 57%, Changodar 27% vs. ₹6,630 Cr order book)
Management tone defensive; deflected on Moraiya gap ('no major reason'), CRGO tariff ('won't comment')
Working capital cycle at 170 days; inventory hoarding through Dec 2026 adds financing drag
FII ownership down 300 bps (11.33% → 8.33%) since Q4 FY25; DII also trimming
Capacity utilization at Moraiya (57%) and Changodar (27%) unexpectedly low despite ₹6,630 Cr order book
HighManagement offers no credible explanation for Moraiya's underperformance vs. competitors at full capacity. If this is structural (hidden demand softness), revenue ramp will disappoint. Ramp to 60–85% is make-or-break for 25% FY27 guidance.
Q1 revenue growth (8.1% YoY) falls short of revised 25% FY27 guidance trajectory
HighGuidance already downgraded once (35–40% → 25%); further misses prompt another cut. Q2–Q3 must show material acceleration (15–20% YoY) to hit annual target. Risk: sequential revenue decline continues, pushing FY27 target to 15–20% growth.
PAT fell 4.7% YoY despite revenue +8.1%; no operating leverage visible
HighSignals input cost inflation, unfavorable mix, or both unmitigated by pricing discipline. Q1 EBITDA (15.6% standalone) below 16% guidance; PAT margin (8.9%) below 9–10% target. Backward integration (margin uplift from FY28) is the only lever; if unproven, margin compression deepens.
Backward integration facilities (CTC Q2, Pressboard Q3, Bushing Q4, Fabrication Q1 FY28) have history of delays
HighChangodar expansion slipped multiple times (monsoon, labor, engineering mods). Now on 'revised schedule.' 200–300 bps margin benefit is priced in; failure to deliver is a ₹50–100 Cr EBITDA miss by FY29.
Working capital cycle at 170 days; deliberate raw material hoarding through Dec 2026
MediumProtective inventory buildup for geopolitical risk inflates financing costs and ties up cash. Company targets 120–130 days forward, but reduction contingent on backward integration reducing inventory. Near-term cash flow under pressure.
CRGO steel anti-dumping investigation by DGTR; management vague on mitigation
MediumIf tariffs imposed, raw material costs could rise 5–10%. Company says it's 'protected through December' via inventory; after that, exposure rises. Backward integration (in-house CTC, Pressboard) intended to hedge, but not yet live.
Management tone defensive; guidance downgrade frames as 'realistic'; deflected on key questions
MediumWhen pressed on Moraiya utilization gap, CFO said 'no major reason.' When asked about CRGO tariff, MD said 'won't comment.' Pattern signals caution, not confidence. Trust erodes after multiple downgrades.
FII and DII ownership declining; stock repriced 41% below ATH and below all key moving averages
MediumInstitutional sell-off (FII -300 bps, DII -240 bps) ahead of or concurrent with guidance downgrade. Stock at 52-week lows. Oversold RSI (28.5) can tighten, but downside risk remains if Q2 disappoints.
1 · Q2 FY27 revenue and capacity utilization (Oct–Nov 2026)
Does Moraiya improve from 57% to 65–70%? Does revenue growth accelerate from 8.1% YoY to 15–20%+ YoY? If Changodar commissioning (Aug 2026) begins to flow orders and Moraiya ramps, then 25% FY27 guidance becomes credible. If Q2 revenue is still 8–12% YoY, expect a second guidance cut.
2 · CTC facility commissioning and early margin accretion (Q2 FY27)
First backward integration facility (CTC, 8,000 MTPA) targeted for Q2 commissioning. Does it launch on schedule? Any depreciation or ramp-up costs that offset margin benefit? Early signs of third-party revenue from the ₹800–1,000 Cr pipeline would validate the ₹8,000 Cr FY29 target.
3 · CRGO anti-dumping verdict and working capital normalization (by Dec 2026)
DGTR investigation outcome will determine raw material cost trajectory after inventory hoarding ends. Management's 'protection through December' hinges on no tariff surprise. Also watch: do receivables normalize to 120–130 days by Q3–Q4? Working capital cycle is a cash flow lever.
TARIL is not a broken story, but it's not a confidence story either—not yet. The order book is real, the export credentials are emerging, and the backward integration roadmap is concrete. But Q1 execution (8.1% YoY growth, -4.7% PAT, margin compression, unexplained capacity utilization gap) does not support the revised 25% FY27 guidance. The company has already downgraded once; if Q2 continues to lag, the next cut could land at 15–20% growth, straining the ₹8,000 Cr FY29 target and eroding what remains of management credibility.
The stock is oversold (RSI 28.5, 41% below ATH), and the order book provides a floor—but a floor is not a buy signal. The single number to track from here is Q2 YoY revenue growth. If it clears 15%, the ramp story is alive. If it's still 8–12%, TARIL is a hold-and-wait, pending Changodar and backward integration execution evidence in H2 FY27.
Rating: Hold. Confidence score: 6/10.